Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors
JCO Clinical Cancer Informatics · 2024
DOI: 10.1200/cci.24.00044 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Clinical Cancer Informatics, 2024. Verfasst von Gabriel Roman Souza und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Mobile Applications, Kidney Neoplasms, Smartphone. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Patients with advanced renal cell carcinoma (RCC) face significant challenges, stemming both from the complexities of the disease itself and the adverse effects of treatments. This study evaluated the feasibility and acceptability of a mobile health (mHealth) application tailored for education and symptom management of patients with advanced RCC receiving combined immune checkpoint inhibitor and tyrosine kinase inhibitor (ICI-TKI) therapy. METHODS The primary end points were acceptability and feasibility. Acceptability was defined as the proportion of patients approached who consented to participate, setting a benchmark of at least 50% for this metric. Feasibility was gauged by the completion rate of the intervention among the participants; it required at least 50% of participants to fully complete the intervention and at least 70% to finish half of the administered questionnaires. The secondary end points included knowledge assessment and patient-reported outcomes (PROs). PROs were evaluated using validated instruments. To discern the changes between pre- and post-educational module quiz scores, we used the Wilcoxon signed-rank test. Time-course data of PROs were visualized using line plots and then compared using paired t-tests. RESULTS From November 2022 to July 2023, 20 of 22 (90%) patients approached for the study consented and enrolled. Of the enrolled patients, 60% completed all questionnaires and knowledge assessments at every time point and 75% completed at least half of the surveys and questionnaires. Significant pre/post differences were noted in two of six quizzes in the knowledge assessment. This study population did not experience a significant change in PRO scores after starting therapy. CONCLUSION The mHealth application designed for education and symptom management in patients with advanced RCC undergoing combination ICI-TKI has proven to be both acceptable and feasible, meeting previous research benchmarks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
- Genitourinary Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
- Department of Health Outcomes and Behavior, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
- Participant Research, Interventions, and Measurements Core, H. Lee Moffitt Cancer Center, and Research Institute, Tampa, FL.
- NTRO Clinical Research Operations, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
- Biostatistics and Bioinformatics Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
ORCID-Profile: Gabriel Roman Souza, Youngchul Kim, Heather S L Jim, Philippe E Spiess, Jad Chahoud
Förderung
- NCI NIH HHS
Zitieren
APA
Roman Souza, G., Turner, K., Gullapalli, K., Paravathaneni, M., Ionescu, F., Semaan, A., DeJesus, A. B., Trujillo, G., Le, C., Kim, Y., Sun, X., Raymond, S., Schneider, A., Manley, B., Jain, R., Gilbert, S., Jim, H. S. L., Spiess, P. E., & Chahoud, J. (2024). Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.24.00044
Vancouver
Roman Souza G, Turner K, Gullapalli K, Paravathaneni M, Ionescu F, Semaan A, et al. Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors. JCO Clinical Cancer Informatics. 2024. doi:10.1200/cci.24.00044
BibTeX
@article{RomanSouza2024,
author = {Roman Souza, Gabriel and Turner, Kea and Gullapalli, Keerthi and Paravathaneni, Mahati and Ionescu, Filip and Semaan, Adele and DeJesus, Amayla Budet and Trujillo, Gillian and Le, Casey and Kim, Youngchul and Sun, Xiaoqi and Raymond, Sarah and Schneider, Amy and Manley, Brandon and Jain, Rohit and Gilbert, Scott and Jim, Heather S L and Spiess, Philippe E and Chahoud, Jad},
title = {Feasibility of a Smartphone Application for Education and Symptom Management of Patients With Renal Cell Carcinoma on Combined Tyrosine Kinase and Immune Checkpoint Inhibitors},
journal = {JCO Clinical Cancer Informatics},
year = {2024},
doi = {10.1200/cci.24.00044}
}
EUVIMED